Loading...
•
Jun 30, 2022
Celcuity Q2 2022 Earnings Report
Celcuity's Q2 2022 financial results were announced, and a corporate update was provided.
Key Takeaways
Celcuity reported a net loss of $10.0 million for the second quarter of 2022, compared to a net loss of $14.0 million for the second quarter of 2021. The company's operating expenses were $9.6 million, and R&D expenses were $8.4 million. Celcuity had cash and cash equivalents of $66.9 million as of June 30, 2022.
Breakthrough Therapy Designation was granted to gedatolisib by the FDA.
Early phase study of gedatolisib in combination with palbociclib and fulvestrant showed promising efficacy and tolerability.
Phase 3 clinical trial, VIKTORIA-1, remains on track to dose the first patient in the next few months.
A $100 million private placement and an amendment to increase the debt financing facility to $75 million are expected to fund operations through 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...